Bleakley Financial Group LLC Sells 1,903 Shares of DexCom, Inc. (NASDAQ:DXCM)

Bleakley Financial Group LLC trimmed its holdings in DexCom, Inc. (NASDAQ:DXCM) by 26.5% in the 3rd quarter, Holdings Channel reports. The fund owned 5,290 shares of the medical device company’s stock after selling 1,903 shares during the quarter. Bleakley Financial Group LLC’s holdings in DexCom were worth $355,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of DXCM. Ballentine Partners LLC increased its stake in shares of DexCom by 11.8% in the 1st quarter. Ballentine Partners LLC now owns 2,517 shares of the medical device company’s stock worth $349,000 after acquiring an additional 266 shares in the last quarter. Global Assets Advisory LLC bought a new position in shares of DexCom in the 1st quarter worth about $2,296,000. Harbor Investment Advisory LLC increased its stake in shares of DexCom by 13.1% in the 1st quarter. Harbor Investment Advisory LLC now owns 864 shares of the medical device company’s stock worth $120,000 after acquiring an additional 100 shares in the last quarter. Riverview Trust Co bought a new position in shares of DexCom in the 1st quarter worth about $32,000. Finally, Sound Income Strategies LLC increased its stake in DexCom by 41.7% during the 1st quarter. Sound Income Strategies LLC now owns 340 shares of the medical device company’s stock valued at $47,000 after purchasing an additional 100 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Performance

DXCM opened at $73.08 on Wednesday. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The company has a market cap of $29.06 billion, a price-to-earnings ratio of 47.15, a PEG ratio of 2.16 and a beta of 1.18. The company’s 50 day moving average is $70.03 and its 200 day moving average is $99.06. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm’s revenue was up 15.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.34 earnings per share. On average, equities research analysts predict that DexCom, Inc. will post 1.69 EPS for the current year.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other DexCom news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the transaction, the executive vice president now directly owns 66,249 shares in the company, valued at $4,607,617.95. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,824 shares of company stock valued at $126,390. 0.30% of the stock is owned by insiders.

Analysts Set New Price Targets

DXCM has been the subject of a number of analyst reports. Wells Fargo & Company reduced their price objective on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a research note on Friday, July 26th. Barclays reduced their price objective on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research note on Monday, July 29th. Oppenheimer reduced their price objective on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, July 26th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, October 12th. Finally, JPMorgan Chase & Co. lowered shares of DexCom from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $145.00 to $75.00 in a research note on Friday, July 26th. Seven equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $110.73.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.